increase of space post photo long

For immediate release: 10/31/2016

Clearwater, Florida – Today CoreRx, Inc. announced plans for continued expansion of its drug product development and manufacturing capabilities in Clearwater, Florida. The expansion will take place in the ICOT center campus in a third buildingwhich will include the following:  15,000 square feet of space for a new warehouse, offices, and additional  manufacturing which includes suites that can support GMP requirements for international clinical studies.

With the new expansion, CoreRx’s clients now have access to over 120,000 square feet of space at the ICOT center campus. The additional expansions should be completed by the middle of Q2 2017, and will include 35 additional employees to the Clearwater workforce over time.

This new build out comes on the heels of CoreRx nearing completion of its previous growth efforts to its first building in the ICOT center campus.  This build out consisted of 5 new manufacturing suites, and also added large scale capacity to its Wet Granulation/Fluid Bed Processing operations.

“This is an exciting time for CoreRx, but our growth has presented real challenges with regard to space within our previous existing facilities, both to accommodate the new equipment required to manufacture an ever-expanding range of products, and the numerous people that we are currently recruiting for all aspects of our business,” said Todd R. Daviau, President and CEO. “The new site acquisition and proposed additions to our operations are a necessary part of ensuring for the longer term that we can continue to prosper and create high quality jobs in the area.”

About CoreRx, Inc.

CoreRx, a Contract Development Manufacturing Organization (CDMO) with a focus on clinical phase drug product development, offering state of the art facilities to support your supply chain needs throughout the entire clinical trial process. Our integrated offerings provide comprehensive services for the development, manufacturing and testing of solid, liquid and semi-solid dosage forms.
Keep on top of new developments at CoreRx and throughout the drug development industry by following– more detailed information about the company, visit

For further information, please contact:
CoreRx – Marketing Director, Michelle Hall or 727-259-6950